Denali Therapeutics announced that results from its open-label Phase 1/2 trial of tividenofusp alfa for Hunter syndrome were published in the January 1, 2026 issue of The New England Journal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback